Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608177 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02608177: Completed NA study, sponsored by University of Washington.
NCT02608177 is a NA study that has completed, run by University of Washington. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608177, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
Primary Outcome
Time with glucose 70-140 mg/dL
Interventions
- DRUG Glipizide
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-08 |
| Phase | NA |
What the finished NCT02608177 record still lists
NCT02608177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT02608177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02608177 about?
NCT02608177 is a clinical study titled "Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management". The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
What is the current status of trial NCT02608177?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2015-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02608177?
The interventions under investigation include: Glipizide (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT02608177?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02608177's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia